LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seeking Alpha reports that bluebird "announced with its Q4 2023 results that the company will have to restate its financials for 2022 and 2023 after finding several accounting errors." The report added that the Company "said the errors relate to the recognition of certain leasing arrangements with contract manufacturers." Based on this news, shares of bluebird fell by more than 13% in intraday trading on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE: The Schall Law Firm
View the original press release on accesswire.com